Patrick M. Brunner

Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial

Emma Guttman‐Yassky, Patrick M. Brunner, Avidan U. Neumann et al. · Journal of the American Academy of Dermatology · 2018 · 328 citations · Full text

The atopic dermatitis blood signature is characterized by increases in inflammatory and cardiovascular risk proteins

Patrick M. Brunner, Mayte Suárez‐Fariñas, Helen He et al. · Scientific Reports · 2017 · 255 citations · Full text

Early-onset pediatric atopic dermatitis is characterized by TH2/TH17/TH22-centered inflammation and lipid alterations

Patrick M. Brunner, Ariel Israel, Ning Zhang et al. · Journal of Allergy and Clinical Immunology · 2018 · 246 citations · Full text

Inflammation, Th2/th17/th22-centered Inflammation, Atopic Dermatitis +8

Efficacy and safety of ustekinumab treatment in adults with moderate‐to‐severe atopic dermatitis

Saakshi Khattri, Patrick M. Brunner, Sandra Garcet et al. · Experimental Dermatology · 2016 · 214 citations · Full text

Allergy Medicine, Immunology, Skin Allergy +18

Single-cell transcriptomics combined with interstitial fluid proteomics defines cell type–specific immune regulation in atopic dermatitis

Thomas B. Rojahn, Vera Vorstandlechner, Thomas Krausgruber et al. · Journal of Allergy and Clinical Immunology · 2020 · 211 citations

Inflammation, Atopic Dermatitis, Immune Cell Development +12